| Japanese |
|---|
| Title | 2つのモノクローナル抗体を組み合わせた新しいCA125測定用IRMAキット「SD-8729」の基礎的検討 |
|---|
| Subtitle | 技術報告 |
|---|
| Authors | 山口敦子*, 小林真理恵*, 今井俊幸*, 大竹英則*, 松原国夫*, 羽鳥昇*, 冨吉勝美*, 井上登美夫*, 遠藤啓吾* |
|---|
| Authors(kana) | |
|---|
| Organization | *群馬大学医学部核医学科・中央放射線部 |
|---|
| Journal | 核医学 |
|---|
| Volume | 30 |
|---|
| Number | 10 |
|---|
| Page | 1245-1252 |
|---|
| Year/Month | 1993/10 |
|---|
| Article | 報告 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」 2つのモノクローナル抗体OC125とM11を組み合わせたone step法IRMAキット「SD-8729」の基礎的, 臨床的検討を行った. OC125抗体のみを125I-標識トレーサ, 固相化抗体として用いたこれまでのキットに比べ, 短い反応時間で, ビーズへの高い結合放射能を示し, 基礎的検討結果は満足すべきものであった. 測定した血中CA125濃度は, これまでのCA125キットによる測定値と非常によく一致した. M11抗体の抗原決定基は, 卵巣癌と反応する抗体130-22, 145-9とも異なるものの一部交叉しており, さらに検討を要する. 「I. はじめに」 卵巣癌の腫瘍マーカーCA 125は, モノクローナル抗体OC125が認識する糖蛋白抗原で, 血中CA 125濃度は卵巣癌, 子宮内膜症の診療に有用である. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | CA125, CA130, Tumor marker, Ovarian cancer. |
|---|
| English |
|---|
| Title | Basic Study of CA125 Measurement Using a Newly Developed "SD-8729" IRMA Kit |
|---|
| Subtitle | Technical Reports |
|---|
| Authors | Atsuko YAMAGUCHI, Marie KOBAYASHI, Toshiyuki IMAI, Hidenori OTAKE, Kunio MATSUBARA, Noboru HATORI, Katsumi TOMIYOSHI, Tomio INOUE, Keigo ENDO |
|---|
| Authors(kana) | |
|---|
| Organization | Department of Nuclear Medicine and Central Radiation Center, School of Medicine, Gunma University |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 30 |
|---|
| Number | 10 |
|---|
| Page | 1245-1252 |
|---|
| Year/Month | 1993/10 |
|---|
| Article | Report |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] "SD-8729" is a one-step IRMA kit employing OC125 antibody as 125I-labeled tracer and M-11 antibody as an immunoadsorbent. Higher boundradioactivity to beads was observed with shorter incubation time than that of a currently used CA125 IRMA kit which employed OC125 antibody both as 125I-labeled ligand and immunoadsorbent attached to beads. Almost identical CA125 values were obtained by using two kits. The antigenic nature recognized by the M-11 antibody seems substantially different from those of 130-22 or 145-9 antibodies recognizing CA130 antigen. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | CA125, CA130, Tumor marker, Ovarian cancer. |
|---|